Azithromycin

Generic Name: Azithromycin

Brand Names: Azasite, Zithromax, Zmax

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₇₂N_₂O_₁₂

CAS Number: 83905-01-5

Unique Ingredient Identifier: J2KLZ20U1M

Background: Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...

Indication: Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis

Associated Therapies: -

Clinical Trials

Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

Not Applicable

Completed

Conditions: Azithromycin
Child Mortality

Interventions: Drug: Azithromycin

First Posted Date: 2020-11-05

Last Posted Date: 2021-07-20

Lead Sponsor: FHI 360

Target Recruit Count: 1735

Registration Number: NCT04617626

Locations: 🇨🇮
Boundiali Health District, Boundiali, Savanes Region, Côte D'Ivoire

Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

Phase 3

Completed

Conditions: Covid19
Infectious Disease
SARS-CoV Infection

Interventions: Drug: Favipiravir
Drug: Azithromycin

First Posted Date: 2020-11-03

Last Posted Date: 2023-03-08

Lead Sponsor: Ina-Respond

Target Recruit Count: 130

Registration Number: NCT04613271

Locations: 🇮🇩
RSPI Sulianti Saroso, Jakarta, DKI Jakarta, Indonesia
🇮🇩
RSJ Soerodjo, Magelang, Central Java, Indonesia
🇮🇩
RSUP Dr. Kariadi, Semarang, Central Of Java, Indonesia

Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Phase 1

Withdrawn

Conditions: Covid19
SARS (Severe Acute Respiratory Syndrome)

Interventions: Drug: Hydroxychloroquine
Dietary Supplement: Vitamins and Minerals
Drug: Azithromycin

First Posted Date: 2020-10-19

Last Posted Date: 2021-12-07

Lead Sponsor: International Brain Research Foundation

Registration Number: NCT04590274

Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia

Phase 3

Withdrawn

Conditions: COVID 19
Patients Hospitalized

Interventions: Drug: HCQ
Drug: Azithromycin
Drug: Doxycycline
Dietary Supplement: Zinc

First Posted Date: 2020-08-27

Last Posted Date: 2020-08-27

Lead Sponsor: Abderrahmane Mami Hospital

Registration Number: NCT04528927

Locations: 🇹🇳
Eshmoun Clinical Research Centre, Tunis, Tunisia

Eosinophil-guided Reduction of Inhaled Corticosteroids

Phase 4

Recruiting

Conditions: COPD
Inhaled Corticosteroid
COPD Exacerbation
Azithromycin
Pneumonia

Interventions: Drug: Azithromycin
Drug: ICS

First Posted Date: 2020-07-22

Last Posted Date: 2024-03-05

Lead Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Target Recruit Count: 444

Registration Number: NCT04481555

Locations: 🇩🇰
Silkeborg Sygehus, Silkeborg, Denmark
🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Hvidovre Hospital, Copenhagen, Denmark

and more 6 locations

Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients

Phase 1

Conditions: Pulmonary Infection
Sars-CoV2
COVID

Interventions: Drug: Oseltamivir
Drug: Azithromycin
Biological: Umbilical Cord Mesenchymal Stem Cells

First Posted Date: 2020-07-07

Last Posted Date: 2020-07-07

Lead Sponsor: Indonesia University

Target Recruit Count: 40

Registration Number: NCT04457609

Locations: 🇮🇩
Sulianti Saroso Center for Infectious Disease, Jakarta, DKI Jakarta, Indonesia
🇮🇩
Universitas Indonesia Hospital, Depok, West Java, Indonesia
🇮🇩
Persahabatan General Hospital, Jakarta, DKI Jakarta, Indonesia

and more 1 locations